6.19

0.98% 0.06

After Hours: 6.05 -0.14 -2.26%

Anteris Technologies Global Corp (AVR)

Overview News Price History Discussions Forecast

Anteris Technologies Global Corp stock is traded at $6.19, with a volume of 407.76K. It is up +0.98% in the last 24 hours and up +12.55% over the past month. Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.

Previous Close:

$6.13

Open:

$6.22

24h Volume:

407.76K

Relative Volume:

0.45

Market Cap:

$601.87M

Revenue:

$1.91M

Net Income/Loss:

$-94.23M

P/E Ratio:

-2.427

EPS:

-2.5505

Net Cash Flow:

$-79.76M

1W Performance:

+8.98%

1M Performance:

+12.55%

6M Performance:

+47.03%

1Y Performance:

+51.72%

1-Day Range:

$6.15

$6.36

1-Week Range:

$5.50

$6.428

52-Week Range:

$2.85

$6.9494

Anteris Technologies Global Corp Stock (AVR) Company Profile

Name

Anteris Technologies Global Corp

Sector

Healthcare (1106)

Industry

Medical Instruments & Supplies (56)

Phone

651-493-0606

Address

860 BLUE GENTIAN ROAD, EAGAN

Employee

174

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

AVR's Discussions on Twitter

Compare AVR vs ISRG, BDX, MDLN, ALC, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVR Anteris Technologies Global Corp	6.19	596.03M	1.91M	-94.23M	-79.76M	-2.5505
ISRG Intuitive Surgical Inc	451.38	160.21B	10.58B	3.00B	2.83B	8.2437
BDX Becton Dickinson Co	144.17	41.62B	21.92B	1.76B	2.63B	6.1223
MDLN Medline Inc	45.32	37.37B	28.43B	1.16B	1.26B	1.4457
ALC Alcon Inc	74.45	35.82B	10.40B	980.00M	1.61B	1.9749
RMD Resmed Inc	207.88	30.38B	5.40B	1.49B	1.78B	10.12

Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	Cantor Fitzgerald	Overweight
Mar-11-26	Initiated	Wells Fargo	Overweight
Jan-08-25	Initiated	Lake Street	Buy
Jan-07-25	Initiated	Barclays	Overweight
Jan-07-25	Initiated	Cantor Fitzgerald	Overweight
Jan-07-25	Initiated	TD Cowen	Buy

View All

Anteris Technologies Global Corp Stock (AVR) Latest News

06:17 AM

First U.S. patients enrolled in Anteris heart valve trial By Investing.com - Investing.com Canada

06:17 AM

06:03 AM

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - The Manila Times

06:03 AM

Anteris Technologies begins U.S. enrollment in heart valve trial - StreetInsider

06:03 AM

First U.S. patients enter Anteris heart valve trial for stenosis - Stock Titan

06:03 AM

May 04, 2026

Anteris Sees CDI Decline as Investors Shift to Nasdaq-Listed Common Stock - TipRanks

May 04, 2026

May 01, 2026

AVR Stock Price, Quote & Chart | ANTERIS TECHNOLOGIES GLOBAL (NASDAQ:AVR) - ChartMill

May 01, 2026

Apr 30, 2026

Anteris Ends v2vmedtech Development Agreement, Limits Exposure - The Globe and Mail

Apr 30, 2026

Anteris Technologies Global Corp. (NASDAQ: AVR) registers 9.10M shares; discontinues v2v contributions - Stock Titan

Apr 30, 2026

Apr 29, 2026

Anteris Technologies Exits v2vmedtech Development Agreement, to Pay $400,000 Break Fee, Shares Up 3% - marketscreener.com

Apr 29, 2026

Anteris Walks Away From v2vmedtech Funding Deal With Limited Financial Impact - TipRanks

Apr 29, 2026

Anteris Technologies ends development agreement with v2vmedtech, pays $400,000 fee - Investing.com

Apr 29, 2026

Anteris Issues 110,236 Restricted Stock Units Under Employee Incentive Plan - TipRanks

Apr 29, 2026

Apr 28, 2026

Anteris Technologies Global (NASDAQ:AVR) Trading 5.7% HigherWhat's Next? - MarketBeat

Apr 28, 2026

Anteris Technologies Global CorpMilestone - Moomoo

Apr 28, 2026

Anteris Technologies Global Corp. Secures Cms Reimbursement Eligibility for Paradigm Trial - marketscreener.com

Apr 28, 2026

Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances - Proactive financial news

Apr 28, 2026

Anteris Wins CMS Reimbursement to Advance PARADIGM Heart Valve Trial in U.S. - TipRanks

Apr 28, 2026

Apr 27, 2026

Anteris Technologies (AVR) registers 9.10M-share resale; files 181K sq ft lease - Stock Titan

Apr 27, 2026

Anteris Technologies Expands Share Base via Conversion of Unquoted Securities - TipRanks

Apr 27, 2026

Apr 26, 2026

Anteris Technologies proposes $200M stock offering, plans Medtronic investment - MSN

Apr 26, 2026

Purchase/sale of business (net) of Anteris Technologies Global Corp. – NASDAQ:AVR - TradingView

Apr 26, 2026

Apr 25, 2026

Wells Fargo initiates coverage of Anteris Technologies Global (AVR) with overweight recommendation - MSN

Apr 25, 2026

Apr 24, 2026

ANTERIS TECHNOLOGIES GLOBAL CORP-ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT - Moomoo

Apr 24, 2026